Fundraising FoxJanus Henderson Investors — 2026 Investments
10 investments dated 2026 · listed companies and verified rows first · show all
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalOrbiMedRA Capital+2 more
AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US
Anar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)
Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsSanofi Ventures
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.
HealthtechMedical DevicesPleasanton, US
Chris Buchko(Executive Officer)inDouglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)inMark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)
BoardRyan Drant(Director)in
Co-investorsQuesta CapitalAlly Bridge Group
Crypto.com operates a cryptocurrency exchange and digital asset platform serving 150 million users across 90 countries, with a mission to accelerate global adoption of cryptocurrency.
Crypto & Web3Fintech
Kris Marszalek(Co-Founder & CEO)inRafael Melo(Co-Founder & CFO)inBobby Bao(Co-Founder, Head of Crypto.com Capital)
Co-investorsMoonhill CapitalAvalanche FoundationBalderton CapitalBlockchain CapitalBNP ParibasBpifrance+10 more
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsAccess BiotechnologyCanaan PartnersSanofi VenturesSV Health InvestorsSR One Capital ManagementBritish Business Bank
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Co-investorsAlly Bridge Groupabrdn plcAngelini VenturesFidelity InvestmentsSanofi Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.